Isavuconazole Kinetic Exploration for Clinical Practice

[1]  T. Walsh,et al.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials , 2018, Antimicrobial Agents and Chemotherapy.

[2]  P. Gubbins,et al.  Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy , 2017, Expert opinion on drug metabolism & toxicology.

[3]  P. Bonate,et al.  Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi , 2017, Antimicrobial Agents and Chemotherapy.

[4]  D. Kowalski,et al.  Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults , 2016, Clinical pharmacology in drug development.

[5]  P. Bonate,et al.  Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi , 2016, Antimicrobial Agents and Chemotherapy.

[6]  P. Bonate,et al.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. , 2016, The Journal of antimicrobial chemotherapy.

[7]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[8]  T. Walsh,et al.  Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis , 2016, Antimicrobial Agents and Chemotherapy.

[9]  S. Seyedmousavi,et al.  Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model , 2015, Antimicrobial Agents and Chemotherapy.

[10]  M. Loriot,et al.  Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  D. Andes,et al.  Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus , 2013, Antimicrobial Agents and Chemotherapy.

[12]  G. Koren,et al.  CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. , 2013, Pharmacogenomics.

[13]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.

[14]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[15]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.